Form 4: Arteris CEO Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
Arteris President and CEO, K. Charles Janac, sold 2,057 shares of common stock for approximately $8.73 per share under a pre-arranged trading plan.
Summary
- K. Charles Janac, President and CEO, Director, and 10% Owner of Arteris, Inc. (AIP), reported a sale of common stock.
- The transaction involved the disposition of 2,057 shares of Common Stock on September 4, 2025.
- The shares were sold at a weighted average price of $8.7255 per share, with individual sales ranging from $8.5750 to $8.8900.
- This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Janac on March 5, 2025.
- Following the transaction, Mr. Janac directly beneficially owns 186,482 shares of Common Stock.
- Indirect beneficial ownership includes 9,839,071 shares through Bayview Legacy, LLC, and 56,252 shares through the Charles and Lydia Janac Trust.
Sentiment
Score: 5
Explanation: The transaction is a pre-scheduled sale under a 10b5-1 trading plan, which is generally considered a neutral event not indicative of immediate insider sentiment regarding company prospects.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Adoption | Reporting Person adopted a Rule 10b5-1 trading plan on March 5, 2025, under which the reported transaction occurred. | March 5, 2025 | Enhances transparency and provides an affirmative defense against insider trading allegations for pre-scheduled trades. |
Related Party Transactions
- Reporting Person indirectly beneficially owns 9,839,071 shares of Common Stock through Bayview Legacy, LLC, where the Reporting Person serves as manager.
- Reporting Person indirectly beneficially owns 56,252 shares of Common Stock through the Charles and Lydia Janac Trust, for which the Reporting Person serves as trustee.
Stakeholder Impact
- Minimal direct impact on shareholders due to the relatively small size of the transaction and its execution under a pre-arranged 10b5-1 plan.
- No immediate impact on employees, customers, suppliers, or creditors is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| March 5, 2025 | 10b5-1 trading plan adopted by Reporting Person. |
| 09/04/2025 | Date of common stock transaction. |
| 09/08/2025 | Date Form 4 was signed/filed. |
Recommendation
holdThis Form 4 reports a routine, pre-scheduled sale of a relatively small number of shares by an insider under a 10b5-1 trading plan. Such transactions are typically for personal financial planning and do not inherently signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing.
Keywords
Arteris, AIP, Form 4, Insider Trading, 10b5-1 Plan, Executive Stock Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.